Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0CCEQO
ADC Name	ABBV-400
Synonyms	ABBV-400; ABBV 400; ABBV400 Click to Show/Hide
Organization	AbbVie, Inc.
Drug Status	Phase 3
Indication	In total 9 Indication(s) Colorectal cancer Phase 3 Clinical Trial Biliary tract cancer Phase 1 Clinical Trial Breast cancer Phase 1 Clinical Trial Head and neck cancer Phase 1 Clinical Trial Liver cancer Phase 1 Clinical Trial Oesophageal cancer Phase 1 Clinical Trial Ovarian cancer Phase 1 Clinical Trial Pancreatic cancer Phase 1 Clinical Trial Solid tumor Phase 1 Clinical Trial
Drug-to-Antibody Ratio	Undisclosed
	3D MOL	2D MOL
Antibody Name	Telisotuzumab		Antibody Info
Antigen Name	Hepatocyte growth factor receptor (MET)		Antigen Info
Payload Name	DNA topoisomerase-I inhibitor		Payload Info
Therapeutic Target	DNA topoisomerase 1 (TOP1)		Target Info
Conjugate Type	Undisclosed
Combination Type	adizutecan